HC Wainwright Reiterates Buy Rating for Aemetis (NASDAQ:AMTX)

HC Wainwright reissued their buy rating on shares of Aemetis (NASDAQ:AMTX) in a research report released on Friday,Benzinga reports. The brokerage currently has a $28.00 price target on the specialty chemicals company’s stock.

Several other equities analysts also recently commented on AMTX. UBS Group cut their price objective on Aemetis from $8.25 to $7.75 and set a “buy” rating on the stock in a research report on Monday, August 19th. Ascendiant Capital Markets dropped their price target on Aemetis from $20.00 to $19.00 and set a “buy” rating on the stock in a research report on Tuesday, September 3rd. Truist Financial reissued a “hold” rating and set a $3.50 price target (down previously from $4.00) on shares of Aemetis in a research report on Wednesday, July 31st. Finally, StockNews.com raised Aemetis to a “sell” rating in a research report on Wednesday, July 31st. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $12.95.

Aemetis Stock Down 1.3 %

Shares of Aemetis stock opened at $3.78 on Friday. The stock’s fifty day moving average is $2.83 and its two-hundred day moving average is $3.05. The company has a market capitalization of $188.00 million, a PE ratio of -1.67 and a beta of 1.23. Aemetis has a 52 week low of $2.10 and a 52 week high of $7.03.

Aemetis (NASDAQ:AMTX) last announced its quarterly earnings data on Tuesday, November 12th. The specialty chemicals company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.09. The business had revenue of $81.44 million during the quarter, compared to the consensus estimate of $77.79 million. During the same period last year, the company earned ($0.59) EPS. As a group, research analysts anticipate that Aemetis will post -2.1 earnings per share for the current year.

Institutional Investors Weigh In On Aemetis

A number of institutional investors have recently added to or reduced their stakes in the stock. State Street Corp raised its stake in shares of Aemetis by 36.1% in the third quarter. State Street Corp now owns 699,089 shares of the specialty chemicals company’s stock worth $1,608,000 after purchasing an additional 185,304 shares during the last quarter. Bank of New York Mellon Corp purchased a new position in shares of Aemetis in the second quarter worth about $306,000. Susquehanna Fundamental Investments LLC raised its stake in shares of Aemetis by 287.4% in the second quarter. Susquehanna Fundamental Investments LLC now owns 126,078 shares of the specialty chemicals company’s stock worth $379,000 after purchasing an additional 93,536 shares during the last quarter. Wellington Management Group LLP purchased a new position in shares of Aemetis in the third quarter worth about $177,000. Finally, Geode Capital Management LLC raised its stake in shares of Aemetis by 7.7% in the third quarter. Geode Capital Management LLC now owns 924,293 shares of the specialty chemicals company’s stock worth $2,126,000 after purchasing an additional 66,031 shares during the last quarter. Institutional investors own 27.02% of the company’s stock.

Aemetis Company Profile

Aemetis, Inc operates as a renewable natural gas and renewable fuels company. It operates through three segments: California Ethanol, California Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the operation, acquisition, development, and commercialization of technologies to produce low and negative carbon intensity renewable fuels that replace fossil-based products.